Curis Lifesciences has been fined Rs 5,900 by the National Stock Exchange of India Limited (NSE) for delayed compliance with listing regulations for the year ended March 2026. The penalty, which includes GST, was imposed due to noncompliance with Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The intimation regarding the fine was received by the company via an email dated June 30, 2026. The communication cited a delay in compliance with the specific regulation and referenced the SEBI Master Circular issued on July 11, 2023. The company is required to pay the amount within 15 days from the date of the notice.

In its filing to the exchange, Curis Lifesciences stated that the financial impact of this development is limited to the fine amount. The disclosure was made in accordance with Regulation 30 of the SEBI Listing Regulations and a specific SEBI circular dated July 13, 2023.

The following table details the penalty information:

The confirmation of the details was provided by Jaimik Mansukhlal Patel, Director of Curis Lifesciences, in the regulatory filing submitted on July 1, 2026.

Promoters of Curis Lifesciences have confirmed that no new encumbrances were created on shares held by the promoter group or Persons Acting in Concert during the financial year ended March 31, 2026. The disclosure, dated April 3, 2026, was submitted to the National Stock Exchange of India Limited and the company's Audit Committee. This declaration ensures transparency regarding the pledging or hypothecation of promoter shares, a key metric for investor risk assessment.

The compliance was filed under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The regulation mandates annual disclosures by promoters regarding any encumbrance on shares held directly or indirectly. The confirmations were provided by Jaimik Mansukhlal Patel, Dharmesh Dasharathbhai Patel, Piyush Gordhanbhai Antala, and Siddhant Jayantibhai Pawasia.

Promoter Disclosures

The following table summarizes the disclosures made by the promoters:

Each promoter explicitly stated that no encumbrance was made other than those already disclosed to the exchanges. The letters addressed to the Manager of the National Stock Exchange and the Chairman of the Audit Committee of Curis Lifesciences Limited were signed and submitted for record purposes.